N-substituted nonaryl-heterocyclo amidyl NMDA/NR2B Antagonists

A compound having the Formula (I):

• 687
• or a pharmaceutically acceptable salt thereof, wherein
• Non Ar is a nonaromatic 5-7 membered ring containing a) 1 nitrogen ring atom, b) 2 nitrogen ring atoms, c) 1 nitrogen and 1 oxygen ring atom, or d) 1 nitrogen and 1 sulfur ring atom, wherein the remaining ring atoms are carbon;
• A is a phenyl optionally substituted with 1-5 substituents, each substituent independently is C1-4alkyl, C3-7cycloalkyl, —CF3, halogen, —OH, —CN, imidazolyl, —C0-4alkyl-N(C0-5alkyl)(C0-5alkyl), —O—C1-4alkyl, —C(O)—C0-4alkyl, —C(O)—O—C0-4alkyl, —O—C(O)—C0-4alkyl, —O—C(O)—C0-4alkylphenyl, —C0-4alkyl—N(C0-5alkyl)-C(O)—C0-4alkyl, —C0-4alkyl-N(C0-5alkyl)-C(O)—O—C0-4alkyl, —C0-4alkyl-N(C0-5alkyl)-C(O)—O—C1-4alkyl, or —NHSO2—C1-4alkyl, —O—C1-4alkylphenyl, or hydroxyiminoethyl;
• any alkyl optionally substituted with 1-6 —OH or halogen;
• or
• A is pyrrolyl, imidazolyl, pyrazolyl, triazolyl, thiophenyl, thiazolyl, thiadiazolyl, oxazolyl, or isoxazolyl, each optionally substituted with 1-3 substituents, each substituent independently is —C1-4alkyl, —C3-7cycloalkyl, —CF3, halogen, —OH, —CN, —C1-4alkoxyl, phenyl, —C0-4alkyl-N(C0-5alkyl)(C0-5alkyl), —C1-4 hydroxyalkyl;
• or
• A is pyridyl, pyradazinyl, pyrimidinyl, or pyrazinyl, each optionally substituted with 1-5 substituents;
• each substituent independently is —C1-4alkyl, —C3-7cycloalkyl, —CF3, halogen, —OH, —CN, phenyl, pyrrolidinyl, azepanyl, —C1-4hydroxyalkyl, —C1-4alkoxy, (CH3)2N—(CH2)2—NH—, —SO2—C1-4alkyl, —C0-4alkyl-N(C0-5alkyl)(C0-5alkyl), —C0-4alkyl-N(C3-6cycloalkyl)(C0-5alkyl), —C0-4alkyl-N(C0-5alkyl)(C1-4alkyloxyC1-4alkyl), —N(C0-5alkyl)-C0-4alkyl-phenyl(C1-4alkoxyl)0-3, —N(C0-5alkyl)—C0-4alkylthiaphenyl, dimethoxyphenyl-CH2—NH—;
• any phenyl optionally substituted with 1-5 —OH, halogen, or C1-4alkyl;
• any alkyl optionally substituted with 1-5 —OH or halogen;
• or the substituent taken with a neighboring bond is ═O;
• or
• A is pyrrolophenyl, imidazolophenyl, pyrazolophenyl, triazolophenyl, pyridinoirnidazolyl, naphthyridinyl, tetrahydrocyclopentopyrazolyl, quinolinyl, pyrimidinopyrazololyl, benzothiazolyl, benzoimidazolyl, benzoxazolonyl, oxodihydrobenzoxazolyl, indolinonyl, oxadihydroquinolinyl, oxatetrahydroquinolinyl, or purinyl, each optionally substituted with 1-5 substituents, each substituent independently is —C1-4alkyl, —C3-7cycloalkyl, —CF3, halogen, —OH, or —CN;
• B is aryl(CH2)0-3—O—(CH2)0-2—C(O)—, heteroaryl(CH2)1-3—O—(CH2)0-2—C(O)—, indanyl(CH2)0-3—O—(CH2)0-2—C(O)—, aryl(CH2)1-3—C(O)—(CH2)0-2—, aryl-cyclopropyl-C(O)—(CH2)0-2—, heteroaryl(CH2)1-3—C(O)—, aryl(CH2)1-3—, heteroaryl(CH2)1-3—, aryl(CH2)1-3—NH—C(O)—, aryl(CH2)1-3—NH—C(NCN)—, aryl(CH2)1-3—SO2—, aryl(CH2)0-3—S—(CH2)0-2—C(O)—, or heteroaryl(CH2)1-3—SO2— wherein any of the aryl or heteroaryl is optionally substituted by 1-5 substituents, each substituent independently is C1-4alkyl, C3-6cycloalkyl, C1-4alkoxy, trifluoromethyl, phenyl, —O—C1-4alkylphenyl, —S(O)—C1-4alkyl, bromo, fluoro, chloro, or 2 substituents together form methylene dioxy;
• any (CH2) optionally is substituted with C1-2alkyl;
• or
• 688
• wherein the phenyl is optionally substituted by 1-3 substituents, each substituent independently is C1-4alkyl, C3-6cycloalkyl, C1-4alkoxy, trifluoromethyl, bromo, fluoro, or chloro;
• and
• X is H, OH, F, C1-4alkyl, C1-4alkoxy, —N(C0-5alkyl)(C0-5alkyl), phenyl, or ═O.